Cargando…

Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2

SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Santiago, Llipsy, Uranga-Murillo, Iratxe, Arias, Maykel, González-Ramírez, Andrés Manuel, Macías-León, Javier, Moreo, Eduardo, Redrado, Sergio, García-García, Ana, Taleb, Víctor, Lira-Navarrete, Erandi, Hurtado-Guerrero, Ramón, Aguilo, Nacho, del Mar Encabo-Berzosa, Maria, Hidalgo, Sandra, Galvez, Eva M., Ramirez-Labrada, Ariel, de Miguel, Diego, Benito, Rafael, Miranda, Patricia, Fernández, Antonio, Domingo, José María, Serrano, Laura, Yuste, Cristina, Villanueva-Saz, Sergio, Paño-Pardo, José Ramón, Pardo, Julián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001978/
https://www.ncbi.nlm.nih.gov/pubmed/33801808
http://dx.doi.org/10.3390/biology10030208
_version_ 1783671356149202944
author Santiago, Llipsy
Uranga-Murillo, Iratxe
Arias, Maykel
González-Ramírez, Andrés Manuel
Macías-León, Javier
Moreo, Eduardo
Redrado, Sergio
García-García, Ana
Taleb, Víctor
Lira-Navarrete, Erandi
Hurtado-Guerrero, Ramón
Aguilo, Nacho
del Mar Encabo-Berzosa, Maria
Hidalgo, Sandra
Galvez, Eva M.
Ramirez-Labrada, Ariel
de Miguel, Diego
Benito, Rafael
Miranda, Patricia
Fernández, Antonio
Domingo, José María
Serrano, Laura
Yuste, Cristina
Villanueva-Saz, Sergio
Paño-Pardo, José Ramón
Pardo, Julián
author_facet Santiago, Llipsy
Uranga-Murillo, Iratxe
Arias, Maykel
González-Ramírez, Andrés Manuel
Macías-León, Javier
Moreo, Eduardo
Redrado, Sergio
García-García, Ana
Taleb, Víctor
Lira-Navarrete, Erandi
Hurtado-Guerrero, Ramón
Aguilo, Nacho
del Mar Encabo-Berzosa, Maria
Hidalgo, Sandra
Galvez, Eva M.
Ramirez-Labrada, Ariel
de Miguel, Diego
Benito, Rafael
Miranda, Patricia
Fernández, Antonio
Domingo, José María
Serrano, Laura
Yuste, Cristina
Villanueva-Saz, Sergio
Paño-Pardo, José Ramón
Pardo, Julián
author_sort Santiago, Llipsy
collection PubMed
description SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. ABSTRACT: Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
format Online
Article
Text
id pubmed-8001978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80019782021-03-28 Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 Santiago, Llipsy Uranga-Murillo, Iratxe Arias, Maykel González-Ramírez, Andrés Manuel Macías-León, Javier Moreo, Eduardo Redrado, Sergio García-García, Ana Taleb, Víctor Lira-Navarrete, Erandi Hurtado-Guerrero, Ramón Aguilo, Nacho del Mar Encabo-Berzosa, Maria Hidalgo, Sandra Galvez, Eva M. Ramirez-Labrada, Ariel de Miguel, Diego Benito, Rafael Miranda, Patricia Fernández, Antonio Domingo, José María Serrano, Laura Yuste, Cristina Villanueva-Saz, Sergio Paño-Pardo, José Ramón Pardo, Julián Biology (Basel) Article SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. ABSTRACT: Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2. MDPI 2021-03-10 /pmc/articles/PMC8001978/ /pubmed/33801808 http://dx.doi.org/10.3390/biology10030208 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Santiago, Llipsy
Uranga-Murillo, Iratxe
Arias, Maykel
González-Ramírez, Andrés Manuel
Macías-León, Javier
Moreo, Eduardo
Redrado, Sergio
García-García, Ana
Taleb, Víctor
Lira-Navarrete, Erandi
Hurtado-Guerrero, Ramón
Aguilo, Nacho
del Mar Encabo-Berzosa, Maria
Hidalgo, Sandra
Galvez, Eva M.
Ramirez-Labrada, Ariel
de Miguel, Diego
Benito, Rafael
Miranda, Patricia
Fernández, Antonio
Domingo, José María
Serrano, Laura
Yuste, Cristina
Villanueva-Saz, Sergio
Paño-Pardo, José Ramón
Pardo, Julián
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title_full Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title_fullStr Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title_full_unstemmed Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title_short Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
title_sort determination of the concentration of igg against the spike receptor-binding domain that predicts the viral neutralizing activity of convalescent plasma and serum against sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001978/
https://www.ncbi.nlm.nih.gov/pubmed/33801808
http://dx.doi.org/10.3390/biology10030208
work_keys_str_mv AT santiagollipsy determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT urangamurilloiratxe determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT ariasmaykel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT gonzalezramirezandresmanuel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT maciasleonjavier determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT moreoeduardo determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT redradosergio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT garciagarciaana determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT talebvictor determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT liranavarreteerandi determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT hurtadoguerreroramon determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT aguilonacho determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT delmarencaboberzosamaria determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT hidalgosandra determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT galvezevam determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT ramirezlabradaariel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT demigueldiego determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT benitorafael determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT mirandapatricia determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT fernandezantonio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT domingojosemaria determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT serranolaura determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT yustecristina determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT villanuevasazsergio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT panopardojoseramon determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2
AT pardojulian determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2